

**Acknowledgment and Consent for Disclosure of
18 U.S.C. §208
Particular Matter Waiver**

Name: Andrew Winokur, M.D.
Committee: Psychopharmacologic Drugs Advisory Committee
Meeting Date: February 6, 2008

I acknowledge that contingent upon public disclosure of the following financial interest submitted on my FDA Form 3410 and related to the agenda item: NDA 22-173 Zyprexa Adhera (olanzapine pamoate depot) long acting intramuscular (IM) injection 210mg, 300mg, and 405mg per/vial, sponsored by Eli Lilly & Company, for treatment of schizophrenia, I am eligible to receive a particular matter waiver under 18 U.S.C. §208.

Type of Interest	Involvement	Magnitude
Employer's study of a competing product for unrelated indication	Competitor	Less than \$100,001 year

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of this interest, the waiver is not valid.

_____/S/_____
Signature

_____/1/3/08_____
Date